• Telix Pharmaceuticals will hold an extraordinary general meeting in November 2026.
• Shareholders will vote on the proposed merger to acquire ITM Isotope Technologies Munich for upfront consideration of USD 1.65 billion.
• The deal includes payment of about USD 1.25 billion in Telix shares, assumption of USD 302 million net debt, closing adjustments.
• Meeting agenda also covers potential contingent consideration of up to USD 700 million tied to FDA approvals and ITM-11 sales milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609202154PR_NEWS_EURO_ND__EN52258) on September 21, 2026, and is solely responsible for the information contained therein.